pan-Canadian Pharmaceutical Alliance

Conducting collective expert-informed negotiations for drugs.

 

Recent Updates

COVID-19: The pCPA is closely monitoring the COVID-19 situation and has implemented measures to ensure negotiations continue as capacity allows. Some negotiations may be temporarily put on hold or delayed during this unprecedented time.

The pCPA will continue to closely monitor the situation and adapt as necessary.

The pan-Canadian Pharmaceutical Alliance (pCPA) is an alliance of the provincial, territorial and federal governments that collaborates on a range of public drug plan initiatives to increase and manage access to clinically effective and affordable drug treatments.

One of pCPA’s key roles is to conduct joint negotiations for brand name and generic drugs in Canada in order to achieve greater value for publicly funded drug programs and patients through its combined negotiating power. Its objectives are to:

  • increase access to clinically effective and cost-effective drug treatment options;
  • achieve consistent and lower drug costs for participating jurisdictions;
  • reduce duplication of effort and improve use of resources; and
  • improve consistency of decisions among participating jurisdictions.

Member Jurisdictions

The pCPA member jurisdictions include public drug plans from: